POS0870 PATIENTS WITH SYSTEMIC SCLEROSIS HAVE IMPAIRED FORCED VITAL CAPACITY, EVEN IN THE ABSENCE OF INTERSTITIAL LUNG DISEASE
Authors: H. Fretheim, I. Barua, Ø. Midtvedt, T. Garen, P. P. Diep, M. Durheim, C. Brunborg, A. M. Hoffmann-Vold
Journal: Annals of the Rheumatic Diseases (2022)

Background Spirometry, in particular forced vital capacity (FVC), is a widely implemented tool in the initial diagnostic workup and monitoring of systemic sclerosis-related interstitial lung disease (SSc-ILD). In addition to ILD, several other extra-pulmonary complications can affect pulmonary function. There is currently limited data on lung function in SSc patients with and without ILD compared to a healthy reference population. Objectives To compare forced vital capacity (FVC) of a well-defined SSc patient cohort with and without ILD to multi-ethnic reference values provided by the European Respiratory Society (ERS) global lung function initiative (1). Methods SSc patients from the Oslo University hospital SSc cohort with at least one PFT were included. We registered each patient’s first available FVC value and a follow-up FVC at 12 +/- 3 months if available. We registered clinical characteristics including sex, age, height, the extent of skin changes, and presence of ILD assessed on HRCT. Predicted FVC values from the reference population were calculated using the GLI 2012 equation (1), including age, height and ethnicity. Descriptive statistics were applied. Results In total, 404 SSc patients were included; of these 58 (14%) patients were anti-Scl 70-antibody positive, 61 (15%) were male, 155 (38%) had ILD and 93 (23%) had diffuse cutaneous SSc (dcSSc). At baseline, mean age was 55.8 (SD 14.0) years, and mean time from first non-Raynaud symptom was 35 (53.2) months. A follow-up spirometry at 12 +/-3 months was available in 164 (41%) patients. Mean FVC was 0.48 L lower at baseline compared to the reference population. At 12 +/-3 months the SSc cohorts mean FVC was 0.39 L lower compared to the reference group (Table 1). The low FVC values at baseline were most pronounced in patients with ILD (0.87L), in male patients (0.86L) and in anti—Scl 70 positive patients (0.67L). But SSc patients with no ILD showed also impaired FVC compared to the reference population (0.24L), even more pronounced when they had dcSSc (0.34L) (Table 1). Table 1. The Oslo SSc cohort Matched controls Difference in L (95% CI) P-value Baseline FVC (n=404), L (SD) 3.14 (0.86) 3.62 (1.13) -0.48 (-0.59, -0.37) &lt;0.001 FVC (male, n=61), L (SD) 3.89 (1.14) 4.75 (0.58) -0.86 (-1.10, -0.66) &lt;0.001 FVC (anti-Scl-70-antibody, n=58), L (SD) 2.98 (0.90) 3.65 (0.75) -0.67 (-0.83, -0.50) &lt;0.001 FVC (dcSSc, n=93), L (SD) 3.06 (0.91) 3.7 (1.00) -0.64 (-0.81, -0.51) &lt;0.001 FVC (ILD, n=155), L (SD) 2.83 (0.78) 3.70 (1.57) -0.87 (-1.13, -0.60) &lt;0.001 FVC (no ILD, n=241), L (SD) 3.32 (0.85) 3.56 (0.74) -0.24 (-0.31, -0.18) &lt;0.001 FVC (no ILD and no skin changes or lcSSc, n=196), L (SD) 3.31 (0.84) 3.53 (0.71) -0.22 (-0.29, -0.15) &lt;0.001 FVC (dcSSc and no ILD, n=43), L (SD) 3.36 (0.89) 3.70 (0.84) -0.34 (-0.52, -0.16) &lt;0.001 12 months follow up FVC (n=164), L (SD) 3.20 (0.86) 3.60 (0.69) -0.39 (-0.49, -0.30) &lt;0.001 FVC (dcSSc, n=39), L (SD) 3.29 (1.00) 3.92 (0.88) -0.63 (-0.87, -0.40) &lt;0.001 FVC (ILD, n=63), L (SD) 2.96 (0.73) 3.66 (0.72) -0.69 (-0.87, 0.52) &lt;0.001 FVC (no ILD, n=97), L (SD) 3.34 (0.90) 3.56 (0.67) -0.21 (-0.31, -0.12) &lt;0.001 Conclusion Mean FVC at baseline was significantly lower in SSc patients compared to the reference population. As expected, SSc patients with ILD had impaired FVC, but also patients without ILD and in patients with limited skin changes. This highlights the importance of other factors than ILD on lung function in SSc patients. References [1]Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations [2]Philip H. Quanjer, Sanja Stanojevic, Tim J. Cole, Xaver Baur, Graham L. Hall, Bruce H. Culver, Paul L.Enright, John L. Hankinson, Mary S.M. Ip, Jinping Zheng, Janet Stocks, the ERS Global Lung Function Initiative. European Respiratory Journal Dec 2012, 40 (6) 1324-1343; DOI: 10.1183/09031936.00080312 Disclosure of Interests Håvard Fretheim Speakers bureau: non-financial support from GSK and Actelion, outside the submitted work., Consultant of: Personal fees from Bayer and non-financial support from GSK and Actelion, outside the submitted work., Imon Barua: None declared, Øyvind Midtvedt: None declared, Torhild Garen: None declared, Phuong Phuong Diep Speakers bureau: PPD has received speaker fees from Boehringer Ingelheim., Michael Durheim Speakers bureau: unpaid consulting/speaking engagements from Boehringer Ingelheim and Roche., Consultant of: previous advisory board participation for Boehringer Ingelheim and Roche, Grant/research support from: research funding (to my institution) from Boehringer Ingelheim and Roche, Cathrine Brunborg: None declared, Anna-Maria Hoffmann-Vold Speakers bureau: Actelion, Boehringer Ingelheim, Jansen, Lilly, Medscape, Merck Sharp &amp; Dohme, Roche, Consultant of: Consultant of: Actelion, ARXX therapeutics, Bayer, Janssen,, MSD, Lilly, Roche, Boehringer-Ingelheim, Medscape.,, Grant/research support from: Boehringer Ingelheim